Welcome to our dedicated page for Amyris news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on Amyris stock.
Amyris, Inc. (Nasdaq: AMRS) is a pioneering synthetic biotechnology company that leverages its Lab-to-Market™ technology platform to facilitate the world's shift towards sustainable consumption. Founded with the vision of transforming the Clean Health & Beauty and Flavors & Fragrances markets, Amyris specializes in converting plant sugars into essential hydrocarbon molecules, specialty ingredients, and consumer products using innovative bioscience solutions. The company's proprietary technology platform utilizes advanced machine learning, robotics, and artificial intelligence to bring new innovations to market at commercial scale, resulting in products incorporated into over 20,000 items from leading global brands, impacting more than 300 million consumers.
Recently, Amyris has undergone significant changes to optimize its operations and financial health. In June 2023, the company announced the resignation of its President & CEO, John Melo, with Han Kieftenbeld stepping in as Interim CEO while continuing his role as CFO. This leadership change aligns with Amyris' broader strategy to streamline its business and achieve cost reduction targets, including a global reduction in force and collaboration with PricewaterhouseCoopers (PwC) to implement 'Fit-to-Win' cost actions estimated at $250 million.
Further advancing its strategic transformation, Amyris commenced voluntary Chapter 11 proceedings in August 2023 to restructure its operations and financial framework. This restructuring aims to enhance the company's cost structure, capital position, and liquidity, allowing it to refocus on its core competencies in research and development, commercialization, and the application of sustainable ingredients through biofermentation. As part of this effort, Amyris plans to exit from its consumer brands, marketing them for sale while continuing to operate them through retail and e-commerce platforms during the transition.
Amyris has secured $190 million in debtor-in-possession financing from Foris Ventures to support its daily operations and meet its commitments to employees, customers, and partners throughout the restructuring process. The company is committed to maintaining its innovative edge and remains dedicated to introducing sustainable, effective, and accessible products to market, ensuring a path toward profitable growth and sustained cash generation.
More information about Amyris and its ongoing projects and initiatives can be found on their official website, www.amyris.com.
Amyris, Inc. (Nasdaq: AMRS) will release its financial results for Q4 and full year 2021 on March 1, 2022, before market opening. CEO John Melo and CFO Han Kieftenbeld will host a conference call at 6:00 a.m. PT (9:00 a.m. ET) to discuss these results and the company's progress. Attendees can access the live webcast through the Investor Relations website. Amyris focuses on sustainable consumption through its Lab-to-Market™ technology, supplying ingredients to major brands and catering to over 300 million consumers worldwide.
Amyris, Inc. (Nasdaq: AMRS) has successfully acquired EcoFabulous, a clean beauty brand targeted at Gen Z consumers, as part of its strategy to enhance growth in the sustainable beauty market. The acquisition complements Amyris' existing consumer brands, which include Rose Inc., JVN, Biossance, Pipette, and Purecane. Furthermore, the company has commenced production at its Reno, Nevada facility ahead of schedule, aiming for product sales to begin in Q3 2022. This move is expected to reduce reliance on third-party manufacturers and improve supply chain efficiency.
Amyris, a synthetic biotechnology company, has appointed Ana Dutra to its Board of Directors, effective January 21, 2022. With over 30 years of experience in global acquisitions and growth strategies, Dutra's expertise is expected to enhance shareholder value. CEO John Melo expressed optimism about her contributions, highlighting her leadership and operational depth. Dutra's background includes significant roles at major corporations, as well as experience in digital technology and ESG initiatives. This appointment comes as Amyris aims to leverage its Lab-to-Market platform for sustainable product innovation.
Amyris, a leading synthetic biotechnology company, announced an agreement to acquire MenoLabs, a women-founded wellness brand, to enhance its entry into the menopause market. This strategic acquisition aims to accelerate growth and establish leadership in a rapidly expanding market, valued at $15 billion and projected to reach $23 billion by 2028. MenoLabs offers all-natural products for menopause symptoms and generates recurring revenue through its subscription model. The acquisition is expected to contribute approximately $30 million in revenue in the first year.
Amyris, a leading synthetic biotechnology company, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 11:15 am ET. This conference serves as a key platform for industry leaders, attracting significant attention from investors and analysts. A live webcast and replay of the presentation will be accessible on Amyris' Investor Relations page. The company focuses on sustainable ingredients in Clean Health & Beauty and Flavors & Fragrances, reaching over 300 million consumers.
Amyris and ImmunityBio have finalized their joint venture to commercialize a next-generation COVID-19 vaccine. This collaboration aims to leverage their combined strengths in vaccine technology and manufacturing capabilities. They plan to begin human trials and seek regulatory approval to deliver the vaccine by 2022, targeting underserved areas affected by vaccine accessibility challenges. The partnership aims to provide robust immunity against COVID-19 variants and adapt to future viruses. Further updates on trial outcomes will be provided as they become available.
Amyris, Inc. (Nasdaq: AMRS) has finalized a joint venture with Minerva Foods to improve the sustainability of animal protein production. The collaboration targets the Brazilian meat export industry, focusing on developing new molecules for reducing carbon intensity and creating sustainable packaging solutions. Regulatory approvals are in place, with expected first license revenue for Amyris by year-end 2021 and initial commercial production slated for 2022. The partnership aims to disrupt the animal protein market while enhancing Amyris' market reach and technology application.
Amyris, a synthetic biotechnology leader, reported unprecedented sales during Black Friday week, achieving over $10 million in consumer sales, doubling last year's figures. This week marked a record-breaking 791,000 visits to its websites, with about 50% of sales generated online. CEO John Melo highlighted successful navigation of supply chain challenges and emphasized the company's commitment to advancing its COVID-19 RNA vaccine trials in South Africa, aiming for regulatory approval to aid global vaccine access.
Amyris, a leader in synthetic biotechnology, will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, at 3:30 pm ET. This event aims to showcase Amyris's innovations in sustainable consumption through its Lab-to-Market™ platform, which combines advanced technology with biotechnology. Interested parties can access a live webcast and replay on the company's Investor Relations page.
Amyris, a synthetic biotechnology company (Nasdaq: AMRS), announced a conference call on November 22, 2021, at 6:00 a.m. PT to discuss its recent financing activity. CEO John Melo and CFO Han Kieftenbeld will lead the discussion. The call is open to all, with a live webcast available at investors.amyris.com. A recording will be available for 90 days. Amyris focuses on sustainable ingredients in Clean Health & Beauty and Flavors & Fragrances markets, utilizing its Lab-to-Market™ platform and innovative technologies.
FAQ
What does Amyris, Inc. specialize in?
What is the Lab-to-Market™ technology platform?
Who is the current CEO of Amyris?
What recent strategic changes has Amyris implemented?
How is Amyris supporting its operations during the restructuring?
What is Amyris' 'Fit-to-Win' initiative?
Will Amyris continue to operate its consumer brands?
What is the impact of Amyris' products on the market?
How can stakeholders get more information about Amyris' restructuring?
Where can I find more information about Amyris?
